𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer

✍ Scribed by Dr. Fikri Içli; Nazan Güunel; Dilek Dinçlol; Handan Karaoǧuz; Ahmet Demirkazik

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
224 KB
Volume
50
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty-nine patients with advanced refractory breast cancer were treated with cisplatin 20 mg/m2/d and VP-16 100 mg/d for 5 days every 3 4 weeks. Ten patients received mitomycin C 10 mg/m2 every 6 weeks additionally. Partial response was obtained in 10 of 26 evaluable patients (38%). The response rates for the group treated with and without mitomycin C were 40% and 37.5%, respectively. Median response duration was 5.5 months in partial responders. Median survival was 9.5 months for partial responders and 2 months for the rest of the patients. Cisplatin and VP-16 combination can be considered as a salvage treatment in heavily pretreated patients with advanced breast cancer.

📜 SIMILAR VOLUMES

Combination chemotherapy in the treatmen
Combination chemotherapy in the treatment of advanced breast cancer
✍ Dutzu Rosner; Takuma Nemoto; Chief Thomas L. Dao 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB

## Abstract Seventy‐two women with metastatic breast cancer were treated with multiple‐agent chemotherapy. Fifty women were treated with 5 drugs in combination: 5‐FU, methotrexate, vincristine, cytoxan, and prednisone; 22 were treated with the combination of 3 drugs: 5‐FU, cytoxan, and prednisone.